Get the Stockscreener App
38.39
0.67%
-0.26
Pre-market:
38.39
Royalty Pharma Plc stock is traded at $38.39, with a volume of 2.80M.
It is down -0.67% in the last 24 hours and up +4.80% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$38.65
Open:
$38.71
24h Volume:
2.80M
Relative Volume:
0.68
Market Cap:
$16.60B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
16.71
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
-3.37%
1M Performance:
+4.80%
6M Performance:
+16.02%
1Y Performance:
+46.41%
1-Day Range:
$38.08
$38.85
1-Week Range:
$37.77
$39.69
52-Week Range:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.39 | 16.51B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Terrance Coyne Sells 69,594 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Why Royalty Pharma plc (RPD) stock could break out in 2025 - newser.com
TD Cowen Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold - MarketBeat
How Royalty Pharma plc (RPD) stock compares with top peersGold Moves & Short-Term Swing Trade Alerts - newser.com
SG Americas Securities LLC Acquires 15,218 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Takes $626,000 Position in Royalty Pharma PLC $RPRX - MarketBeat
Catalyst Funds Management Pty Ltd Trims Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Applying chart zones and confluence areas to Royalty Pharma plc2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
What macro factors could drive Royalty Pharma plc (RPD) stock higher2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Top chart patterns to watch in Royalty Pharma plcJuly 2025 Institutional & Fast Gain Stock Trading Tips - newser.com
VP Lloyd Files To Sell 3,000 Of Royalty Pharma PLC [RPRX] - TradingView
Will Royalty Pharma plc (RPD) stock maintain strong growthTrend Reversal & Precise Buy Zone Identification - newser.com
Royalty Pharma Insider Sold Shares Worth $2,735,329, According to a Recent SEC Filing - MarketScreener
CFO Coyne Sells 69,594 ($2.7M) Of Royalty Pharma PLC [RPRX] - TradingView
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
What MACD signals say about Royalty Pharma plcPortfolio Growth Summary & Intraday High Probability Setup Alerts - newser.com
Historical volatility pattern of Royalty Pharma plc visualizedTrade Exit Summary & Expert Curated Trade Ideas - newser.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targetsBond Market & Long-Term Growth Portfolio Plans - newser.com
Analyzing net buyer seller activity in Royalty Pharma plcTrade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com
Trading the Move, Not the Narrative: (RPRX) Edition - news.stocktradersdaily.com
Is Royalty Pharma plc (RPD) stock attractive post correctionWall Street Watch & Risk Managed Investment Signals - newser.com
Can Royalty Pharma plc stock rebound after recent weaknessWeekly Market Report & High Accuracy Investment Signals - newser.com
Why analysts remain bullish on Royalty Pharma plc stockShare Buyback & Capital Efficient Trading Techniques - newser.com
Royalty Pharma (RPRX): Is the Stock Undervalued After Higher 2025 Revenue Guidance and Major Buyback Completion? - Yahoo Finance
How Analyst Views on Royalty Pharma Are Shifting With Recent Acquisition and Growth Moves - Yahoo Finance UK
Vise Technologies Inc. Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Ontario Teachers Pension Plan Board Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Published on: 2025-11-18 06:12:54 - newser.com
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Nov 17 '25 |
Sale |
39.30 |
69,594 |
2,735,329 |
54,760 |
1.73%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):